Key result
Fast-track PCSK9 inhibitors after ACS are linked to ~88% LDL-C target achievement versus stepwise therapy.
Why the study?
The efficacy of adding PCSK9 inhibitors within 48 hours to oral optimized lipid lowering therapy during ACS hospitalization remains understudied in real-world settings.
Does 'fast track' addition of PCSK9 inhibitors within 48 hours improve LDL-C reduction compared to standard 'stepwise' therapy in patients with acute coronary syndrome?
Cohort (n=128)
No
Does 'fast track' addition of PCSK9 inhibitors within 48 hours improve LDL-C reduction compared to standard 'stepwise' therapy in patients with acute coronary syndrome?
Absolute Event Rate: 88.3% vs 61.9%
p-value: p=<0.001
Fast-track initiation of PCSK9 inhibitors within 48 hours of ACS safely and effectively achieves LDL-C targets more rapidly than standard stepwise therapy in a real-world setting.
Should not yet change ACS lipid management; extends observational data on early PCSK9 inhibitors while leaving randomized confirmation open.
Background The “fast track” addition (within 48 hours) of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) to the oral optimized lipid lowering therapy (LLT) during hospitalization for acute coronary syndrome (ACS) has been shown to rapidly achieve the low–density lipoprotein cholesterol (LDL–C) therapeutic targets. However, so far, its efficacy in real–world settings remains understudied. Methods We retrospectively analyzed 128 ACS patients treated at our center, comparing “PCSK9i fast track” use within 48 hours to standard “stepwise” LLT. Lipid levels and incidence of major adverse cardiovascular events (MACEs) were evaluated at 30 and 180 days. Results The “PCSK9i fast track” group achieved significantly lower LDL–C levels at 30 days (41.5 ± 27.5 vs. 85.6 ± 35.9 mg/dL, p ‹ 0.001) and 180 days (29.6 ± 21.0 vs. 59.0 ± 32.4 mg/dL, p ‹ 0.001). Recommended LDL–C targets (‹55 mg/dL) were met by 88.3% of “PCSK9i fast track” group at 180 days, compared to 61.9% of controls (p ‹ 0.001). No significant differences in MACEs were observed between groups. No adverse effects from PCSK9i use were noted. Conclusions The “PCSK9i fast track” strategy was safe and effective in achieving LDL–C targets more rapidly than conventional approaches in real–world ACS patients.
No takes yet. Share an insight, caveat, or question.
Bellis et al. (2026) conducted a cohort in Acute Coronary Syndrome (n=128). PCSK9 inhibitors fast track use (within 48 hours) vs. Standard stepwise lipid lowering therapy was evaluated on Recommended LDL-C targets (<55 mg/dL) met at 180 days (p=<0.001). Fast track addition of PCSK9 inhibitors within 48 hours of ACS resulted in 88.3% of patients meeting LDL-C targets at 180 days compared to 61.9% with standard stepwise therapy (p<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: